Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

Claudia Baratè,Simona Soverini,Giuseppe Saglio,Luigiana Luciano,Sara Galimberti,Patrizia Pregno,Alessandra Iurlo,Antonio Percesepe,Dianna Maar,Fabio Stagno,Maria Antonella Laginestra,Stefano Pileri,Gianantonio Rosti,Mario Tiribelli,Fausto Castagnetti,Massimiliano Bonifacio,Monica Crugnola,Giovanni Martinelli,Luana Bavaro,Francesca Lunghi,Vanessa Velotta,Gabriele Gugliotta,Michele Baccarani,Caterina De Benedittis,Fabrizio Pane,Margherita Martelli,Mariella D’adda ,Antonella Russo Rossi ,Adam S Corner ,Michèle Cavo

doi:10.1182/blood-2019-126767

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

Claudia Baratè, Simona Soverini + Show 28 more

Open Access

https://doi.org/10.1182/blood-2019-126767

Copy DOI

#Advisory Committees #To Tyrosine Kinase Inhibitors + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

Full Text